The Liver Institute recently hosted an informative symposium to address the growing concern of Metabolic Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD/NASH.

By bringing together healthcare providers from across the DFW area and beyond, the event aimed to enhance awareness and understanding of this increasingly prevalent liver disease.

A Pressing Need for Specialized Care

Despite the rising incidence of hepatobiliary diseases, a shortage of trained providers capable of diagnosing and treating MASLD persists. This gap in expertise often leaves frontline providers ill-equipped to manage these complex patients.

The Liver Institute, in collaboration with Methodist Health System, is committed to addressing this challenge. By hosting this symposium, they provided a valuable platform for healthcare professionals to:

• Advance their knowledge: Learn about the latest diagnostic testing, treatment options, and referral pathways for MASLD.

• Enhance collaboration: Foster partnerships and improve communication between primary care providers and specialists.

• Improve patient outcomes: Equip healthcare providers with the tools and knowledge necessary to optimize patient care.

A Renowned Expert Shares Insights

The symposium featured a keynote presentation by Dr. Nancy S. Reau, MD, a leading expert in hepatology. Dr. Reau discussed the epidemiology, diagnosis, testing, complications, and emerging treatments for MASLD, including both current and investigational therapies.

A Collaborative Effort

The success of this event was made possible by the collaborative efforts of:

• Parvez Mantry, MD: Transplant Hepatologist at The Liver Institute at Methodist Dallas Medical Center

• Mangesh Pagadala, MD: Transplant Hepatologist at The Liver Institute at Methodist Dallas Medical Center

By empowering healthcare providers with the latest information and fostering a collaborative approach, The Liver Institute is making a significant impact on the management and treatment of MASLD.